Circassia Pharmaceuticals’ pipeline has suffered its first notable post-IPO setback. The British biotech’s ragweed allergy drug failed to live up to expectations in a Phase IIb trial, prompting the company to dig deeper into the data in search of a path forward for the candidate. …read more

Source: Circassia looks to higher doses to salvage ragweed drug after PhIIb miss


0 No comments